Evidence map›Paper›PMID 42694107›Full record

ArticleFrontiers in immunology2026

The emergence of putative epistatic mutations and iSNVs in SARS-CoV-2 XBB.1.16 variants linked with alteration in immunogenic determinants.

Mukesh Kumar Jogi, Sristy Shikha, Pushpendra Singh, Devesh Sharma, Shreyansh Shreyansh, Prem Mishra, Aiswariya Priyadarsini, Aahamya Priyadarsini, Deokrishna Kumar Choudhary, Meenu Jain and 8 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mukesh Kumar Jogi *Division of Molecular Biology, Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research, Noida, India.
Sristy Shikha *Division of Molecular Biology, Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research, Noida, India.
Pushpendra Singh *Department of Biotechnology, Central University of Haryana, Mahendergarh, India.
Devesh SharmaDepartment of Biochemistry, Govt Institute of Medical Sciences, Greater Noida, India.
Shreyansh ShreyanshDepartment of Biotechnology, Anugrah Narayan (A.N.) College, Patna, India.
Prem MishraDepartment of Biotechnology, Anugrah Narayan (A.N.) College, Patna, India.
Aiswariya PriyadarsiniDepartment of Biological Sciences, Indian Institute of Science Education and Research (IISER), Berhampur, India.
Aahamya PriyadarsiniDepartment of Biological Sciences, Indian Institute of Science Education and Research (IISER), Berhampur, India.
Deokrishna Kumar ChoudharySchool of Mechanical and Materials Engineering, Indian Institute of Technology (IIT) Mandi, Mandi, Himachal Pradesh, India.
Meenu JainViral Research and Diagnostic Laboratory (VRDL), Gajra Raja Medical College, Gwalior, Madhya Pradesh, India.
Ritu SagarDivision of Molecular Biology, Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research, Noida, India.
Anuj KumarDivision of Molecular Biology, Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research, Noida, India.
Robin MarwalDepartment of Biochemistry, Govt Institute of Medical Sciences, Greater Noida, India.
Md Kausar NeyazDepartment of Biochemistry, Govt Institute of Medical Sciences, Greater Noida, India.
Dheeraj Dube PrakashchandSchool of Mechanical and Materials Engineering, Indian Institute of Technology (IIT) Mandi, Mandi, Himachal Pradesh, India.
Rakesh GuptaDepartment of Biochemistry, Govt Institute of Medical Sciences, Greater Noida, India.
Shalini SinghDivision of Molecular Biology, Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research, Noida, India.
Pramod KumarDivision of Molecular Biology, Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research, Noida, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 XBB variants have been proposed to evolve towards immune evasion against vaccination or natural infection, which may contribute to higher transmissibility. The XBB.1.16 independently emerged due to accumulation of two important substitutions, E180V and T478R in the spike protein. Its pseudoviral infectivity and evasion of humoral immunity were similar to XBB.1 and XBB.1.5. In March 2023, XBB.1.16 had outcompeted other dominant XBB variants in India, which indicate a potential growth advantage. Here, intra-host single nucleotide variations (iSNV) and mutations were screened in SARS-CoV-2 genomes in closely related individuals at two time points: at symptoms onset, and during recovery. The prominence of putative epistatic iSNVs (E180V, G184V, G252V, D253G, and P521S/T) in XBB.1.16 variants were detected during the recovery phase. E180V exhibits mutational constellations with the G252V and P521T in a subset of samples, and this pattern was also detected in contemporary SARS-CoV-2 genomes. Higher order protein structural predictions suggested that the putative epistatic interactions among E180V, G184V, and G252V, D253G may be associated with S protein folding and structural stability. This study involving genomics and computational analyses highlights the potential role of these putative epistatic interactions in immune evasion, which may have contributed to dominance of XBB variants.

Indexed as

COVID-19Epistasis, GeneticSARS-CoV-2Spike Glycoprotein, CoronavirusGenome, ViralHumansImmune EvasionMutationPolymorphism, Single NucleotideSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2epistasisgenomicsimmune evasioniSNVsSARS-CoV2

Identifiers

PMID42694107
PMCPMC13538099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.